Aldosterone synthase inhibitors in hypertension and chronic kidney disease: double the benefit?

Current Opinion in Nephrology and Hypertension · Published 2026-03-12 · DOI 10.1097/mnh.0000000000001175

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1097/mnh.0000000000001175

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• New insights into clinical spectrum of antineutrophil cytoplasmic autoantibody associated disease · Current Opinion in Nephrology and Hypertension · 2026 · Same journal
• Fibroblast growth factor 23 at the crossroads of mineral metabolism and bone disease · Current Opinion in Nephrology and Hypertension · 2026 · Same journal
• Multimorbidity after renal transplantation: incidence and implications for patients · Current Opinion in Nephrology and Hypertension · 2026 · Same journal
• WNK1 is a central osmolality sensor that regulates arginine vasopressin secretion · Current Opinion in Nephrology and Hypertension · 2026 · Same journal
• Financial and policy challenges of delivering kidney replacement therapies in resource-limited settings · Current Opinion in Nephrology and Hypertension · 2026 · Same journal
• Kidney care for children: their needs are different · Current Opinion in Nephrology and Hypertension · 2026 · Same journal
• The podocyte slit-diaphragm: target of anti-nephrin antibodies · Current Opinion in Nephrology and Hypertension · 2026 · Same journal
• Evolution in the targets for blood pressure treatment · Current Opinion in Nephrology and Hypertension · 2025 · Same journal
• Medullary sponge kidney and chronic pain: is there a role for renal denervation · Current Opinion in Nephrology and Hypertension · 2025 · Same journal
• Role of the calcium-sensing receptor in regulating calcium transport in the thick ascending limb · Current Opinion in Nephrology and Hypertension · 2026 · Same journal